OctoPlus tries to get drug-delivery tentacles into generics

OctoPlus, a drug-delivery company based in the Netherlands, is actively looking for partnerships with specialty manufacturers of generic drugs, which OctoPlus believes can benefit from its controlled-release technology. In-PharmaTechnologist reports that OctoPlus sees an extra source of revenue coming from generics that lack the expertise to enter specialty markets.

"Our team has identified a number of high-value opportunities in specialty generics, where we can co-invest and leverage our world-class expertise in formulation development," said Jan Egberts, CEO of OctoPlus, in a news release.

The company's second-quarter results saw increased revenue from drug-delivery technologies, partially offset by a drop in earnings due to support for Locteron, a controlled-release version of interferon. Locteron is undergoing trials to treat hepatitis C. It's based on OctoPlus's PolyActive drug-delivery technology, whose biggest selling points include its biodegradability and low initial release.

PolyActive is one of three drug delivery technologies developed by OctoPlus. The company also boasts of OctoDEX--dextran-based microsphere delivery technology for proteins and particulate systems--and a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules.

- see the story in In-PharmaTechnologist


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.